Rasilez and new Enbrel indication approved in Japan
This article was originally published in Scrip
Executive Summary
Novartis's direct renin inhibitor Rasilez (aliskiren) has been approved in Japan for the treatment of hypertension, either as monotherapy or in combination with other antihypertensives.